BioTech Medics, Inc. (BMCS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.41 means the share price is 0.41 times one year of earnings per share. Beta 3.66: the stock has moved about 266% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBioTech Medics, Inc. (BMCS) trades at $0.0002. BioTech Medics, Inc. operates as a medical-based holding company, providing therapeutic laser centers and nutraceutical products. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for BMCS: BMCS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BioTech Medics, Inc. (BMCS) Healthcare & Pipeline Overview
BioTech Medics, Inc. is a medical-based holding company operating therapeutic laser centers and offering nutraceutical products. The company focuses on pain management and wellness, with laser centers in multiple states and a range of retail products. It competes in the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for BMCS?
BioTech Medics, Inc. presents a unique investment proposition as a medical-based holding company operating therapeutic laser centers and selling nutraceutical products. With a P/E ratio of 0.41 and a beta of 3.66, the company's valuation and volatility should be carefully considered. Key value drivers include the expansion of its laser center network and the growth of its nutraceutical product sales. Potential catalysts include increased consumer demand for alternative pain management solutions and the successful launch of new nutraceutical products. However, investors should be aware of the risks associated with operating in the competitive healthcare market and the challenges of scaling a business with a limited market cap. The company's reliance on retail sales and laser center revenue makes it susceptible to economic fluctuations and changes in consumer behavior.
Based on FMP financials and quantitative analysis
BMCS Key Highlights
Operates medical therapeutic laser centers in Texas, California, New Mexico, and Florida, providing pain management solutions.
- Offers SHBAN, an antiseptic hand and body sanitizer, addressing hygiene needs.
- Develops and sells nutraceutical products, including BioBody Balance and BioBody Energy Spray, through retail sales.
- Incorporated in 1997, indicating a long-standing presence in the healthcare market.
- P/E ratio of 0.41, reflecting its current valuation relative to earnings.
Who Are BMCS's Competitors?
BMCS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.35 | -9.03% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $20.9M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| TXMD TherapeuticsMD, Inc. | $2.01 | -1.95% | $24.0M | — |
| CPHI CPHI | $0.65 | -0.61% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMCS's Key Strengths?
Operates medical therapeutic laser centers.
- Offers a range of nutraceutical products.
- Has a presence in multiple states.
- Proprietary formulations for certain products.
What Are BMCS's Weaknesses?
Limited market capitalization.
- Reliance on retail sales.
- Concentrated geographic presence.
- Dependence on laser center revenue.
What Are the Key Risks for BMCS?
Financial-distress signal — its Altman Z-Score of 0.03 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies with greater resources.
- Changes in healthcare regulations affecting laser therapy or nutraceutical products.
- Economic downturn impacting retail sales of nutraceuticals.
- Product liability claims related to laser therapy or nutraceutical products.
- Limited financial disclosure due to OTC Other tier status.
What Are BMCS's Competitive Advantages?
- Specialized medical therapeutic laser centers offer a unique service.
- Proprietary nutraceutical formulations provide product differentiation.
- Established laser center locations in multiple states create a regional presence.
- Brand recognition in the pain management and wellness market.
What Does BMCS Do?
BioTech Medics, Inc., incorporated in 1997 and based in Southlake, Texas, functions as a medical-based holding company. The company's core business involves operating medical therapeutic laser centers designed to treat various pain ailments affecting muscles, nerves, bones, and arthritis. These laser centers are located in Texas, California, New Mexico, and Florida. In addition to its medical centers, BioTech Medics offers SHBAN, an antiseptic hand and body sanitizer, catering to hygiene needs. The company also develops and sells nutraceutical products, including BioBody Balance, a liquid vitamin concentrate, and BioBody Energy Spray, a caffeine and alcohol-free natural vitamin energy spray. These nutraceuticals are available through gross retail sales, expanding the company's market reach beyond its laser therapy services. BioTech Medics aims to provide integrated healthcare and wellness solutions through its diverse offerings, targeting both medical and retail consumers.
What Products and Services Does BMCS Offer?
- Operates medical therapeutic laser centers for pain management.
- Treats pain ailments affecting muscles, nerves, and bones.
- Offers laser therapy for arthritis.
- Provides SHBAN antiseptic hand and body sanitizer.
- Develops and sells BioBody Balance liquid vitamin concentrate.
- Develops and sells BioBody Energy Spray, a caffeine and alcohol-free energy spray.
- Sells nutraceutical products through retail channels.
How Does BMCS Make Money?
- Generates revenue from laser therapy treatments at its medical centers.
- Earns revenue from the sale of SHBAN antiseptic hand and body sanitizer.
- Generates revenue from the sale of nutraceutical products, including BioBody Balance and BioBody Energy Spray.
- Utilizes gross retail sales for its nutraceutical products.
What Industry Does BMCS Operate In?
BioTech Medics, Inc. operates within the specialty and generic drug manufacturing industry, which is characterized by intense competition and evolving regulatory landscapes. The market for pain management solutions is growing, driven by an aging population and increasing awareness of alternative therapies. The nutraceutical market is also expanding, fueled by consumer interest in health and wellness products. BioTech Medics competes with larger pharmaceutical companies and smaller specialized firms, requiring it to differentiate itself through innovative products and services. The company's success depends on its ability to navigate the competitive landscape and capitalize on emerging market trends.
Who Are BMCS's Key Customers?
- Individuals seeking pain management solutions for muscle, nerve, and bone ailments.
- Patients suffering from arthritis seeking alternative therapies.
- Consumers looking for antiseptic hand and body sanitizers.
- Individuals seeking vitamin supplements and energy boosters.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
BioTech Medics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.03 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for BioTech Medics, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. BMCS trades at a trailing price-to-earnings ratio of 0.41, below the Healthcare sector average of ~21.10x.
Company Profile
BioTech Medics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Southlake, US. The company is led by CEO Anthony Keith Miller. BMCS has traded publicly since 2010.
BMCS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
BMCS Latest News
No recent news available for BMCS.
BMCS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BMCS.
Price Targets
Wall Street price target analysis for BMCS.
BMCS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BMCS; grades run from A+ (80-100) to F (below 30).
Leadership: Anthony Keith Miller
CEO
Anthony Keith Miller serves as the CEO of BioTech Medics, Inc. His background includes experience in the healthcare and wellness industries. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. He leads the management team in executing the company's growth plans and ensuring its long-term success.
Track Record: Specific details regarding Anthony Keith Miller's track record at BioTech Medics, Inc. are not available. His tenure and key achievements are currently unknown. Further information is needed to assess his impact on the company's performance and strategic direction.
BMCS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioTech Medics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases investment risk.
- Low trading volume can lead to price volatility.
- OTC Other tier status indicates higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to listed exchanges.
- Potential for difficulty in selling shares due to limited liquidity.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Check for any legal or regulatory issues involving the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operation of medical therapeutic laser centers in multiple states.
- Development and sale of nutraceutical products.
- Long-standing presence in the healthcare market (incorporated in 1997).
- Physical presence with laser centers in Texas, California, New Mexico, and Florida.
BioTech Medics, Inc. Healthcare Stock: Key Questions Answered
What is BioTech Medics, Inc.'s strategy for expanding its market reach in the pain management sector?
BioTech Medics, Inc. can expand its market reach in the pain management sector through several strategies. These include expanding its network of laser therapy centers to new geographic locations, forming strategic partnerships with healthcare providers, and enhancing its online presence to reach a broader audience.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.